SHARESIFT
In short: Cochlear Limited (COH.AX), a Healthcare company, scores 21/100 on ShareSift's value score and 4/9 on the Piotroski F-Score, with an Altman Z-Score in the safe zone as of 7 October 2026.
Healthcare · data ~15-min delayed
129.5 AUD -0.58%
Open full interactive analysis →| Price | 129.5 AUD |
| Day change | -0.58% |
| Market cap | 8.47B |
| 52-week range | 88.74 – 296.5 |
| P/E (trailing) | 57.6 |
| Dividend yield | 2.00% |
| Payout ratio | 190.94% |
| Return on equity | 7.98% |
| Debt / equity | 12% |
| Beta | 0.24 |
| Sector | Healthcare |
| Value score | 21 / 100 |
How the value score is calculated: 13 published tests, weighted to 100.
Cochlear Limited (COH.AX) scores 21/100 on this site's value model, in the lower band: most of the valuation measures it checks sit on the richer side. It trades at 57.6 times trailing earnings and is classified in Healthcare. The dividend yield is 2.00%, paid from 191% of earnings. Return on equity is 8%, with debt at 12% of equity. On its filings it passes 4 of the nine Piotroski checks, a mixed picture. Its Altman Z-Score places it in the safe zone. These are automated readings of reported figures, not a recommendation.
Piotroski F-Score 4 / 9 — nine pass/fail checks on profitability, leverage and efficiency, comparing the latest financial year with the one before.
Altman Z-Score 7.73 — Safe zone.
Cochlear Limited (COH.AX) scores 21/100 on ShareSift's value score as of 7 October 2026. The score is thirteen published pass/fail tests on reported figures: sixty points for valuation measures such as P/E and price-to-book, and forty for profitability, financial health, growth and dividends. A missing figure counts as a fail.
Cochlear Limited trades at 57.6 times its trailing twelve-month earnings as of 7 October 2026. The price-to-earnings ratio is the share price divided by earnings per share; a lower figure means paying less for each dollar of profit, though growth companies usually carry higher ratios.
Yes. Cochlear Limited has a dividend yield of 2.00% at the current share price as of 7 October 2026, paying out 191% of its earnings. The yield is the annual dividend divided by the price, so it rises when the price falls. Past dividends do not guarantee future ones.
Cochlear Limited passes 4 of the nine Piotroski checks, which ShareSift reads as mixed. The F-Score compares the latest financial year with the one before on profitability, debt and liquidity, and operating efficiency. It shows the direction of the business, not whether the shares are cheap.
Cochlear Limited's Altman Z-Score is 7.73, in the safe zone. The score combines five balance-sheet and earnings ratios to gauge financial-distress risk: above 2.99 is safe, 1.81 to 2.99 grey, and below 1.81 distress. It was built for manufacturers and suits banks poorly.
Prices and fundamentals: Yahoo Finance (unofficial), as of 7 October 2026; prices are delayed about 15 minutes. Piotroski F-Score and Altman Z-Score: Yahoo Finance annual statements, comparing the latest two annual reports. How each score is calculated: value score, F-Score, Z-Score. Every source ShareSift uses: data sources.
Updated · prices ~15-min delayed, fundamentals as last reported
Open full interactive analysis →See how it ranks: ASX stocks by value score
Value scoring · Piotroski F-Score · Altman Z · technicals · dividends — free, no sign-up.